- Home
- RDFN vs ELVN Comparison
RDFN vs ELVN Comparison
Compare RDFN & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDFN
- ELVN
- Stock Information
- Founded
- RDFN 2002
- ELVN 2016
- Country
- RDFN United States
- ELVN United States
- Employees
- RDFN N/A
- ELVN N/A
- Industry
- RDFN Real Estate
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- RDFN Finance
- ELVN Health Care
- Exchange
- RDFN Nasdaq
- ELVN Nasdaq
- Market Cap
- RDFN 1.3B
- ELVN 927.8M
- IPO Year
- RDFN 2017
- ELVN 2020
- Fundamental
- Price
- RDFN $11.12
- ELVN $21.36
- Analyst Decision
- RDFN Hold
- ELVN Strong Buy
- Analyst Count
- RDFN 11
- ELVN 5
- Target Price
- RDFN $10.85
- ELVN $39.60
- AVG Volume (30 Days)
- RDFN 6.6M
- ELVN 716.7K
- Earning Date
- RDFN 08-05-2025
- ELVN 08-12-2025
- Dividend Yield
- RDFN N/A
- ELVN N/A
- EPS Growth
- RDFN N/A
- ELVN N/A
- EPS
- RDFN N/A
- ELVN N/A
- Revenue
- RDFN $1,038,527,000.00
- ELVN N/A
- Revenue This Year
- RDFN N/A
- ELVN N/A
- Revenue Next Year
- RDFN $5.32
- ELVN N/A
- P/E Ratio
- RDFN N/A
- ELVN N/A
- Revenue Growth
- RDFN 5.11
- ELVN N/A
- 52 Week Low
- RDFN $5.49
- ELVN $13.30
- 52 Week High
- RDFN $15.29
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- RDFN 62.34
- ELVN 55.84
- Support Level
- RDFN $10.29
- ELVN $20.22
- Resistance Level
- RDFN $11.84
- ELVN $24.11
- Average True Range (ATR)
- RDFN 0.48
- ELVN 1.69
- MACD
- RDFN 0.08
- ELVN -0.02
- Stochastic Oscillator
- RDFN 79.34
- ELVN 53.58
About RDFN Redfin Corporation
Redfin Corp is a residential real estate broker. It pairs its agents with the technology to create a service that is faster and costs less. The company meets customers through a listings-search website and mobile application. The company uses the same combination of technology and local service to originate mortgage loans and offer title and settlement services. It has five operating segments real estate services, rentals, mortgage, title, and monetization. The company generates the majority of its revenue from Real estate services.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.